Cargando…
Co-prescription of Dual-Antiplatelet Therapy and Proton Pump Inhibitors: Current Guidelines
Dual-antiplatelet therapy (DAPT) prevents thrombotic complications associated with coronary artery disease, acute coronary syndrome, and stent thrombosis following the percutaneous coronary intervention or coronary artery bypass grafting. When initiating DAPT, the risk of thrombosis must be balanced...
Autores principales: | Saven, Hannah, Zhong, Lynna, McFarlane, Isabel M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901154/ https://www.ncbi.nlm.nih.gov/pubmed/35273851 http://dx.doi.org/10.7759/cureus.21885 |
Ejemplares similares
-
Proton Pump Inhibitors: Exploring Cardiovascular Complications and Prescription Protocol
por: Sarnaik, Mubashira K, et al.
Publicado: (2021) -
Antiplatelet agents and proton pump inhibitors – personalizing treatment
por: Lin, Eugene, et al.
Publicado: (2010) -
Hypomagnesemia Caused by Chronic Use of Over-the-Counter Proton Pump Inhibitor as a Possible Cause of Supraventricular Tachycardia
por: Ortega, Francisco J, et al.
Publicado: (2023) -
Formation of a Rectus Sheath Hematoma Secondary to COPD Exacerbation While Taking Dual Antiplatelet Therapy
por: Salem, Nicholas, et al.
Publicado: (2021) -
A Case of Bilateral Hemorrhagic Pleural Effusion Due to Dual Antiplatelet Therapy in a Dialysis Patient
por: Jahir, Tahmina, et al.
Publicado: (2022)